🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Pertuzumab

Also listed in trial records as TQB2440
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 38 trials in our China, USA, UK and India registers that name Pertuzumab as an intervention. Synced 24 Sep 2026
38Trials tracked
14Recruiting now
30Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Pertuzumab is named as a drug or biological intervention in 38 clinical trials in our China, USA, UK and India trial registers, 14 of which are recruiting. Lead sponsors include AstraZeneca (3), Shanghai Jiao Tong University School of Medicine (3) and Genentech, Inc. (2). Registered phases: Phase 2, Phase 3, Phase 1/2, Phase 1, Phase 2/3 and Phase 4. Conditions studied include Breast Cancer; HER2-positive Breast Cancer; Breast Neoplasms.

01

Clinical trials of Pertuzumab

38 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07003074 A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Breast Cancer
 Phase 3 Recruiting Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. China
NCT07377643 IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (ClinicalTrials.gov ↗)
HER2-positive Breast Cancer
 Phase 3 Recruiting Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. China
NCT07441460 A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (ClinicalTrials.gov ↗)
Resectable HER2-positive Breast Cancer
 Phase 3 Recruiting Shanghai JMT-Bio Inc. China
NCT07518173 A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer (ClinicalTrials.gov ↗)
HER2-positive Breast Cancer
 Phase 3 Recruiting Sichuan Baili Pharmaceutical Co., Ltd. China
NCT07797218 Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC (ClinicalTrials.gov ↗)
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
 Phase 3 Recruiting Shanghai Jiao Tong University School of Medicine China
NCT05638594 Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 2 Recruiting Shengjing Hospital China
NCT06145308 Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (ClinicalTrials.gov ↗)
Salivary Gland Carcinoma, Precision Therapy
 Phase 2 Recruiting Peking Union Medical College China
NCT07102381 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
HER2-positive Breast Cancer, Breast Cancer
 Phase 2 Recruiting Jazz Pharmaceuticals USA
NCT07393425 Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer (ClinicalTrials.gov ↗)
HER2 + Breast Cancer
 Phase 2 Recruiting Shanghai Jiao Tong University School of Medicine China
NCT07616427 Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (ClinicalTrials.gov ↗)
HR+/HER2+ Early Breast Cancer
 Phase 2 Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine China
NCT07647263 Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer (ClinicalTrials.gov ↗)
HER2-positive Breast Cancer
 Phase 2 Recruiting The First Affiliated Hospital of Soochow University China
NCT05150691 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
HER2-positive Advanced Solid Tumor
 Phase 1/2 Recruiting DualityBio Inc. USA, China
NCT06686394 Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (ClinicalTrials.gov ↗)
Breast Neoplasms, Breast Cancer
 Phase 1/2 Recruiting Merck Sharp & Dohme LLC UK, USA
NCT07140393 A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor (ClinicalTrials.gov ↗)
Solid Tumor
 Phase 1/2 Recruiting Jiangsu HengRui Medicine Co., Ltd. China
NCT07093931 Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 4 Not yet open Shandong Cancer Hospital and Institute China
NCT05983094 Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer, Neoadjuvant Therapy
 Phase 2 Not yet open Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT06510465 Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 2 Not yet open RenJi Hospital China
NCT07136974 Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. (ClinicalTrials.gov ↗)
Breast Cancer, HER2 + Breast Cancer
 Phase 2 Not yet open Henan Cancer Hospital China
NCT07246317 Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 2 Not yet open Tianjin Medical University Cancer Institute and Hospital China
NCT07528898 Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 2 Not yet open Hebei Medical University Fourth Hospital China
NCT07716111 Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma (ClinicalTrials.gov ↗)
Gastric or Gastroesophageal Junction Adenocarcinoma
 Phase 2 Not yet open The First Affiliated Hospital with Nanjing Medical University China
NCT07795424 Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer, HR Positive, HER2 Positive Breast Cancer
 Phase 2 Not yet open Shengjing Hospital China
NCT04193059 Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 3 Active, closed Fudan University China
NCT04208178 Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (ClinicalTrials.gov ↗)
Advanced HER2+Breast Cancer
 Phase 3 Active, closed Novartis Pharmaceuticals USA, China
NCT04514419 Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 3 Active, closed BioRay Pharmaceutical Co., Ltd. China
NCT04784715 Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Breast Cancer; HER2-positive; Metastatic
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT05113251 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
 Phase 3 Active, closed AstraZeneca USA, India, China
NCT05132582 A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (ClinicalTrials.gov ↗)
HER2 Positive Breast Cancer
 Phase 3 Active, closed Seagen, a wholly owned subsidiary of Pfizer UK, USA, China
NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer (ClinicalTrials.gov ↗)
Early or Locally Advanced HER2-positive Breast Cancer
 Phase 3 Active, closed Shanghai JMT-Bio Inc. China
NCT05426486 A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients (ClinicalTrials.gov ↗)
HER2-positive Breast Cancer
 Phase 2/3 Active, closed Caigang Liu China
NCT00781612 A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies (ClinicalTrials.gov ↗)
Neoplasm Metastasis
 Phase 2 Active, closed Genentech, Inc. UK, USA, China
NCT04172259 ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
Breast Cancer, Neoadjuvant Chemotherapy
 Phase 2 Active, closed Sun Yat-sen University China
NCT04398914 Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer Invasive
 Phase 2 Active, closed Shanghai Jiao Tong University School of Medicine China
NCT04538742 A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Metastatic Breast Cancer
 Phase 1/2 Active, closed AstraZeneca UK, USA, India
NCT06771622 Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗)
Solid Cancer
 Phase 1/2 Active, closed FBD Biologics Limited China
NCT02057133 A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (ClinicalTrials.gov ↗)
Breast Neoplasms
 Phase 1 Active, closed Eli Lilly and Company USA
NCT03006172 To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Breast Cancer, Solid Tumor
 Phase 1 Active, closed Genentech, Inc. UK, USA
NCT04188548 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
 Phase 1 Active, closed Eli Lilly and Company USA, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

26 conditions
Condition (as registered)Trials
Breast Cancer17
HER2-positive Breast Cancer5
Breast Neoplasms3
Metastatic Breast Cancer2
Solid Tumor2
HER2 + Breast Cancer2
Breast Cancer; HER2-positive; Metastatic1
Neoplasm Metastasis1
HER2 Positive Breast Cancer1
Advanced Breast Cancer1
Endometrial Cancer1
HER2-positive Advanced Solid Tumor1
Advanced HER2+Breast Cancer1
HER2-positive Early Breast Cancer1
Neoadjuvant Chemotherapy1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)1
HR Positive, HER2 Positive Breast Cancer1
Salivary Gland Carcinoma1
Precision Therapy1
Resectable HER2-positive Breast Cancer1
Early or Locally Advanced HER2-positive Breast Cancer1
Neoadjuvant Therapy1
Gastric or Gastroesophageal Junction Adenocarcinoma1
HR+/HER2+ Early Breast Cancer1
Solid Cancer1
Breast Cancer Invasive1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
AstraZeneca3
Shanghai Jiao Tong University School of Medicine3
Genentech, Inc.2
Eli Lilly and Company2
Shengjing Hospital2
Shanghai JMT-Bio Inc.2
Merck Sharp & Dohme LLC1
Seagen, a wholly owned subsidiary of Pfizer1
Jazz Pharmaceuticals1
DualityBio Inc.1
Novartis Pharmaceuticals1
Sun Yat-sen University1
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1
Jiangsu HengRui Medicine Co., Ltd.1
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.1
Peking Union Medical College1
The First Affiliated Hospital of Soochow University1
Fudan University1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Tianjin Medical University Cancer Institute and Hospital1
The First Affiliated Hospital with Nanjing Medical University1
Sichuan Baili Pharmaceutical Co., Ltd.1
Second Affiliated Hospital, Zhejiang University, School of Medicine1
Caigang Liu1
Henan Cancer Hospital1
RenJi Hospital1
BioRay Pharmaceutical Co., Ltd.1
Shandong Cancer Hospital and Institute1
FBD Biologics Limited1
Hebei Medical University Fourth Hospital1
04

Trials by country register

RegisterPertuzumab trials
Clinical trials in China33
Clinical trials in USA12
Clinical trials in UK6
Clinical trials in India3

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pertuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pertuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.